These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 36750229)

  • 1. Real-world evaluation of a two-step testing algorithm for
    Hecker MT; Son AH; Zuccaro P; Conti J; Donskey CJ
    Infect Control Hosp Epidemiol; 2023 Sep; 44(9):1494-1496. PubMed ID: 36750229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential underreporting of treated patients using a
    Guh AY; Fridkin S; Goodenough D; Winston LG; Johnston H; Basiliere E; Olson D; Wilson CD; Watkins JJ; Korhonen L; Gerding DN
    Infect Control Hosp Epidemiol; 2024 May; 45(5):590-598. PubMed ID: 38268440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A cost of illness comparison for toxigenic Clostridioides difficile diagnosis algorithms in developing countries.
    Cançado GGL; Abreu ES; Nardelli MJ; Serwa P; Brachmann M
    Anaerobe; 2021 Aug; 70():102390. PubMed ID: 34058377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toxin Enzyme Immunoassays Detect Clostridioides difficile Infection With Greater Severity and Higher Recurrence Rates.
    Guh AY; Hatfield KM; Winston LG; Martin B; Johnston H; Brousseau G; Farley MM; Wilson L; Perlmutter R; Phipps EC; Dumyati GK; Nelson D; Hatwar T; Kainer MA; Paulick AL; Karlsson M; Gerding DN; McDonald LC
    Clin Infect Dis; 2019 Oct; 69(10):1667-1674. PubMed ID: 30615074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implementing a Clostridium difficile testing algorithm and its effect on isolation duration and treatment initiation: a pre- and post-implementation study.
    Vogelzang EH; Lankelma JM; van Mansfeld R; van Prehn J; van Houdt R
    Eur J Clin Microbiol Infect Dis; 2020 Jun; 39(6):1071-1076. PubMed ID: 31970532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Performance of Clostridium difficile toxin enzyme immunoassay and nucleic acid amplification tests stratified by patient disease severity.
    Humphries RM; Uslan DZ; Rubin Z
    J Clin Microbiol; 2013 Mar; 51(3):869-73. PubMed ID: 23269736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Host Immune Markers Distinguish Clostridioides difficile Infection From Asymptomatic Carriage and Non-C. difficile Diarrhea.
    Kelly CP; Chen X; Williams D; Xu H; Cuddemi CA; Daugherty K; Barrett C; Miller M; Foussadier A; Lantz A; Banz A; Pollock NR
    Clin Infect Dis; 2020 Mar; 70(6):1083-1093. PubMed ID: 31211839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction in testing and change in testing algorithm associated with decrease in number of nosocomial Clostridioides (Clostridium) difficile infections.
    Cook PP; Nichols S; Coogan M; Opera J; DeHart M
    Am J Infect Control; 2020 Sep; 48(9):1019-1022. PubMed ID: 32044135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of
    Dumm RE; Burnham C-AD; Hink T; Reske KA; Struttmann E; Iqbal ZH; Cass C; Kwon JH; Olsen MA; Dubberke ER
    J Clin Microbiol; 2024 Jan; 62(1):e0103723. PubMed ID: 38078766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preventable Patient Harm: a Multidisciplinary, Bundled Approach to Reducing Clostridium difficile Infections While Using a Glutamate Dehydrogenase/Toxin Immunochromatographic Assay/Nucleic Acid Amplification Test Diagnostic Algorithm.
    Schultz K; Sickbert-Bennett E; Marx A; Weber DJ; DiBiase LM; Campbell-Bright S; Bode LE; Baker M; Belhorn T; Buchanan M; Goldbach S; Harden J; Hoke E; Huenniger B; Juliano JJ; Langston M; Ritchie H; Rutala WA; Smith J; Summerlin-Long S; Teal L; Gilligan P
    J Clin Microbiol; 2018 Sep; 56(9):. PubMed ID: 29997201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of the introduction of nucleic acid amplification testing on Clostridioides difficile detection and ribotype distribution in Wales.
    Perry MD; White PL; Morris TE
    Anaerobe; 2021 Feb; 67():102313. PubMed ID: 33309680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A 2-step algorithm combining glutamate dehydrogenase and nucleic acid amplification tests for the detection of Clostridioides difficile in stool specimens.
    Liu C; Tang C; Han Y; Xu Y; Ni F; Jin K; Liu G
    Eur J Clin Microbiol Infect Dis; 2021 Feb; 40(2):345-351. PubMed ID: 32944896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential introduction of a multistep testing algorithm and nucleic acid amplification testing leading to an increase in
    Skinner AM; Yu B; Cheknis A; Pacheco SM; Gerding DN; Johnson S
    Infect Control Hosp Epidemiol; 2020 Oct; 41(10):1148-1153. PubMed ID: 32576334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two-step Testing for Clostridioides Difficile is Inadequate in Differentiating Infection From Colonization in Children.
    Parnell JM; Fazili I; Bloch SC; Lacy DB; Garcia-Lopez VA; Bernard R; Skaar EP; Edwards KM; Nicholson MR
    J Pediatr Gastroenterol Nutr; 2021 Mar; 72(3):378-383. PubMed ID: 32925555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clostridioides difficile Infection in Cancer and Immunocompromised Patients: Relevance of a Two-step Diagnostic Algorithm and Infecting Ribotypes on Clinical Outcomes.
    Yepez Guevara EA; Aitken SL; Olvera AV; Carlin L; Fernandes KE; Bhatti MM; Garey KW; Adachi J; Okhuysen PC
    Clin Infect Dis; 2021 May; 72(10):e460-e465. PubMed ID: 32803229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trends in Clostridioides difficile diagnosis before and after a change in testing algorithm.
    Turner DP; Thorburn SJ; Crowe A; Jardine D; Timmins C
    J Microbiol Methods; 2021 May; 184():106189. PubMed ID: 33689797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of Clostridioides difficile Infection-Related Complications and Treatment Patterns among Nucleic Acid Amplification Test-Positive/Toxin Enzyme Immunoassay-Negative Patients.
    Miller R; Morillas JA; Brizendine KD; Fraser TG
    J Clin Microbiol; 2020 Feb; 58(3):. PubMed ID: 31896665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Superiority of the DNA amplification assay for the diagnosis of C. difficile infection: a clinical comparison of fecal tests.
    Barkin JA; Nandi N; Miller N; Grace A; Barkin JS; Sussman DA
    Dig Dis Sci; 2012 Oct; 57(10):2592-9. PubMed ID: 22576711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of mandatory nucleic acid amplification test (NAAT) testing approval on hospital-onset
    McCormick WL; Jackson G; Andrea SB; Whitehead V; Chargualaf TL; Touzard-Romo F
    Infect Control Hosp Epidemiol; 2024 Jan; 45(1):106-109. PubMed ID: 37424227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nucleic Acid Amplification Test Quantitation as Predictor of Toxin Presence in Clostridium difficile Infection.
    Crobach MJT; Duszenko N; Terveer EM; Verduin CM; Kuijper EJ
    J Clin Microbiol; 2018 Mar; 56(3):. PubMed ID: 29237788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.